Table 9.
Summary of other singleton therapy study characteristics and VC outcome
| Author and Year | Type of Study | Study Duration (months) | Participant | Intervention (Participants at Baseline) | Comparator (Participants at Baseline) | VC as Primary or Secondary End Point | VC Imaging | VC Site | VC Outcome |
|---|---|---|---|---|---|---|---|---|---|
| Raggi 2020134 (CaLIPSO) | RCT | 12 (52 weeks) | HD | SNF472 600 mg, n=91 | SNF472 300 mg, n=92 | Placebo, n=91 | Primary | CT | Coronary artery | Less progression with SNF472 |
| Gueiros 2019135 | RCT | 12 | PD | Spironolactone daily, n=16 | Treatment as usual, n=17 | Primary | CT | Coronary artery | No significant VC attenuation |
| Coyne 2019136 | RCT | 7 (225 days) | HD, anemia | Sotatercept 0.3 mg/kg, n=9 | 0.5 mg/kg, n=8 | 0.7 mg/kg, n=9 | 0.7/0.4 mg/kg, n=6 | Placebo, n=11 | Secondary | CT | Abdominal aorta | Less progression with sotatercept |
| Liu 2020137 | RCT | 12 | HD | Nicotinamide + calcium-based phosphate binder, n=49 | Placebo + calcium-based phosphate binder, n=49 | Secondary | X-ray lateral | Abdominal aorta | No significant VC attenuation |
| Gao 2019138 | RCT | 24 | CKD stage 3–4 | Phase 2: oral activated charcoal, n=17 | Lanthanum carbonate, n=17 Calcium carbonate, n=16 | Primary during the second phase | CT | Coronary artery | VC progressed least with lanthanum followed by charcoal then calcium |
HD, hemodialysis; PD, peritoneal dialysis.